Skip to main
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity is a clinical-stage biotechnology company that has a positive outlook as its lead therapeutic candidate, Revtorpyk (gedatolisib), has shown potential in targeting multiple nodes of the PI3K/AKT/mTOR pathway and overcoming adaptive resistance mechanisms. With data showing efficacy in HR+/HER2- breast cancer and ongoing trials for other solid tumors, and a successful commercial launch planned for late 3Q26, indications are that Celcuity could be a strong competitor in the market. With promising treatment duration data and solid financials, Celcuity is poised for success.

Bears say

Celcuity is expected to face declining sales as competition intensifies in the HR+/HER2- metastatic breast cancer market, and the company's high-priced drug, gedatolisib, may not be able to maintain its expected peak sales of over $2.5 billion. In addition, the company's financials show increased expenses and a high net loss, which could negatively impact investor perception of the company's prospects. Overall, the combination of competitive challenges and financial risks suggests a negative outlook for Celcuity's stock.

Celcuity (CELC) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Celcuity (CELC) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $153.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $153.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.